Strattera

Strattera Contraindications

atomoxetine

Manufacturer:

Eli Lilly

Distributor:

DKSH
Full Prescribing Info
Contraindications
Strattera is contraindicated in patients with: Known hypersensitivity to atomoxetine or any excipients in Strattera.
Symptomatic cardiovascular disease - moderate to severe hypertension, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, or ventricular flutter, advanced arteriosclerosis (see Precautions).
Severe cardiac or vascular disorders whose condition would be expected to deteriorate if they experienced increases in blood pressure or in heart rate that could be clinically important (for example, 15 to 20 mmHg in blood pressure or 20 beats per minute in heart rate) (see Cardiovascular Effects under Precautions).
Uncontrolled hyperthyroidism.
Phaeochromocytoma or a history of phaeochromocytoma (see Cardiovascular Effects under Precautions).
Monoamine Oxidase Inhibitors (MAOI) - Strattera should not be taken with MAOI or within 2 weeks after discontinuing MAOI. Treatment with MAOI should not be initiated within 2 weeks after discontinuing Strattera.
With other drugs that affect brain monoamine concentrations, there have been reports of serious, sometimes fatal, reactions when taken in combination with MAOI. These reactions include hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs and mental status changes that include extreme agitation progressing to delirium and coma, some cases presented with features resembling neuroleptic malignant syndrome. Such reactions may occur when these drugs are given concurrently or in close proximity.
Narrow Angle Glaucoma - In clinical studies, the use of Strattera was associated with an increased risk of mydriasis and therefore its use is not recommended in patients with narrow angle glaucoma.
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $139 a year.
Sign up for free
Already a member? Sign in